Member Info for mulledwine

One to watch when economies sorted out

The future Our job is to help employers change the way they recruit and retain talent, and we continue to witness a greater demand for the wide range of services we have developed. As employers create more resourcing and talent functions they increasingly need to buy in expertise. That is good news for us as we sell the expertise they need. The Group today is substantially different from that which came to the AIM market in 2006. Since then the business environment has changed beyond recognition, and today Work Group is better placed with better skills to exploit the reality of changing economic conditions. Simon Howard Chairman

Preliminary Results Work Group plc (LSE - AIM: "WORK") announces preliminary results for the year ended 31 December 2011. Headlines · Gross profit (net fee income) up 5% to £13.1m (2010: £12.5m) · Operating profit before exceptional items was £0.5m (2010: £0.3m) · Cash at year end down 25% to £1.3m (2010: £1.8m) · Strong balance sheet and zero bank debt The operating profit after exceptional costs was £0.1m (2010: £0.2m loss). Exceptional costs principally relating to redundancies and office rationalisation were £0.5m (2010: £0.5m).

http://www.investegate.co.uk/Article.aspx?id=201203150700133779Z

ACOJE NICKEL LATERITE RESOURCE UPDATE AND ZCMC INFILL DRILLING PROGRAM 15 March 2012 - ENK plc ('ENK' or the 'Company') (AIM, PLUS, ASX: ENK) is pleased to announce the completion of the infill drilling program and nickel limonite and saprolite resource update for the Acoje Project as well as an update on the nickel laterite infill drill program for the Zambales Chromite Mining Corporation ('ZCMC') Project. Both projects are located in close proximity on the west coast of Luzon, 250 kilometres north of Manila in the Philippines. The updated Indicated and Inferred JORC (2004) Resource estimate at a 0.8% Ni cut-off for Acoje, as prepared by Snowden Industry Mining Consultants ('Snowden') of Perth, Australia, is: Indicated: 40.9 million tonnes grading 1.08% Ni, 0.05% Co Inferred: 29.0 million tonnes grading 0.96% Ni, 0.06% Co Representing a total of over 720,000 tonnes of contained nickel at the Acoje Project alone. This represents an increase of 36% in contained nickel from the November 2008 resource estimate1 following the completion of an extensive infill drilling program at Acoje. Nearly all of the Inferred material reported in the 2008 estimate has been converted to Indicated and a further 20 million tonnes has been delineated (seven million tonnes Indicated and 13 million tonnes Inferred). In addition, the resource estimate includes a complete detailed re-domaining of the orebody to incorporate the substantial metallurgical data that has been obtained for the deposit. Furthermore, a comprehensive bulk density determination program was combined with the infill drill program to further enhance the already robust resource interpretation. A direct comparison of changes to Indicated and Inferred material in the 2008 resource estimate cannot be made due to the re-domaining and changes in bulk densities.

http://www.investegate.co.uk/Article.aspx?id=201203150700204032Z

"Shire has had a close partnership with the global Fabry patient community for over 10 years, and we are extremely disappointed that we feel compelled to make this decision," said Sylvie Grégoire, President, Shire HGT.

KeywordCompanyEPIC/TIDMSEDOL/ISINNews Price Announcements Fundamentals News Article RSS Shire plc (SHP) Add to Alerts list Print Mail a friend Thursday 15 March, 2012 Shire plc Shire Update on US BLA Filing for REPLAGAL® Shire Provides Update on US Biologics License Application Filing for REPLAGAL® (agalsidase alfa) Lexington, Massachusetts, US - March 14, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has withdrawn its Biologics License Application (BLA) for REPLAGAL® (agalsidase alfa) with the US Food and Drug Administration (FDA). Shire has been in ongoing dialogue with the FDA since the supply shortage of the only US approved treatment for Fabry disease. In 2009, and again in 2011, the FDA encouraged Shire to submit an application for the approval of REPLAGAL. The information in the application included relevant updates such as manufacturing and open long-term clinical trial data. These discussions led the Company to file a BLA last November in anticipation of a quick review process and eventual approval - allowing Shire to supply more US patients with a therapy they desperately needed at the time. Recent interactions with the FDA have led the Company to believe that the agency will require additional controlled trials for approval. No concerns over the product's safety profile were raised by the FDA. Shire has concluded that the likely additional studies would cause a significant delay, and an approval of REPLAGAL for US patients would only be possible in the distant future. Shire has therefore decided to withdraw its BLA.

http://www.investegate.co.uk/Article.aspx?id=20120315070000P462D

Pre-close year end statement Datatec, ("Datatec" or the "Group", JSE and LSE: DTC), the international Information and Communications Technology ("ICT") group, is today publishing a year-end trading update for the financial year ended 29 February 2012. The Group's profitability and earnings for the full year are expected to be in line with the original forecasts published during 2011 and confirmed in the Interim Management Statement on 18 January 2012 ("IMS"). Since the Group reported its IMS on 18 January 2012, conditions have remained challenging in North America and Europe. There have been signs of recovery emerging in the US, however the environment in the UK is still very weak. Latin America, in particular Brazil, had another period of exceptional performance. For the financial year ending 29 February 2012, the Group expects revenues of approximately $5 billion (2011: $4.3 billion), profit after tax* of approximately $84 million (2011: $46 million), underlying** earnings per share of approximately 47 US cents (2011: 37.9 US cents) and both earnings* and headline* earnings per shareof approximately 42 US cents (2011: 22.8 and 23.9 US cents respectively). The Group expects to release its full year results for the financial year ending 29 February 2012 on or about Wednesday 16 May 2012. The financial information on which this statement is based has not been reviewed and reported on by Datatec's external auditors.

http://www.investegate.co.uk/Article.aspx?id=201203150700113716Z

Deltex Medical Group (DEMG) also benefited from news of a successful trial, as reports that its CardioQ-ODM technology reduced patient's post-operative length of hospital stay by 40%, sent the company's shares 2.125p higher to 24.25p. The technology, which controls fluid management during bowel surgery, was tested across six hospitals in British Colombia, Canada, and was also able to reduce the number of complications patients experienced after the surgery. The findings create the argument that the technology would be a hugely advantageous piece of equipment to have in any operation room.

Shares in SocialGO (SGO) plummeted 0.275p to 0.875p as pre-tax losses widened 9.2% to 1.18 million pounds in the 31st December 2011, despite the social network website developer posting a 27% jump in sales to 734,000 pounds. 2011 marked the launch of SocialGo version 2, management noting the accelerated commercialisation of the technology, which it believes will continue to drive the business forward in the coming year. Unsatisfied investors were perhaps expecting a little more from the numbers, which would explain why the shares have fallen back considerably, having gained as much as 70% in the weeks prior to the release.

FJ- - they certainly did !

Peel Hunt upgrades Marston's from hold to buy, target price raised from 100p to 114p

Insulation and specialty construction firm SIG (SHI) saw improved trading conditions and increased market volumes over the year ended 31st December 2011, resulting in a pre-tax profits of 7.5 million pounds, compared to a loss of 80.8 million pounds in 2010. The firm enjoyed a strong performance in mainland Europe, with revenues rising 11.3% to 1.5 billion pounds, accounting for 56% of total sales. The shares climbed 4.4p to 119.9p.

Commenting on the results and outlook, Chris Davies, Chief Executive, said: "We are pleased with these results and the progress we are making. I would highlight in particular the success of our organic growth strategy, with new branches moving into profitability more quickly than anticipated. "During 2011 the Group delivered on a number of key objectives. Operationally, we continued to outperform the market while improving gross margins and securing additional efficiency savings. Strategically, we increased focus on our three core markets of insulation & energy management, interiors and exteriors by divesting non-core operations. Financially, we improved returns and further strengthened our balance sheet. "We enter 2012 as a much leaner, stronger and more focused organisation. Sales per day in constant currency so far this year were around 1% ahead of strong prior year comparators, despite the impact of severe weather across Mainland Europe in February this year. "Given the current uncertainties in the macroeconomic environment, we continue to expect market volumes to be slightly down overall in 2012. However, we have a solid platform on which to build and are targeting further market outperformance, with new branches expected to make a significant contribution to future growth."

Financial highlights · Sales from continuing operations up by 7.8% to £2,744.8m (7.1% in constant currency) · Gross margin in continuing operations improved by 20bps to 25.6% (2010: 25.4%) · Underlying operating margin in continuing operations up by 40bps to 3.5% (2010: 3.1%) · Underlying profit before tax from continuing operations increased by 27.3% to £81.7m · Statutory profit before tax increased to £7.5m (2010: loss of £80.8m) · Net debt of £115.9m, reduced by £69.1m compared to 31 December 2010 - leverage now less than 1x (net debt/EBITDA) · Return on capital employed (post-tax) increased by 230bps to 7.9% (2010: 5.6%) · Proposed final dividend of 1.5p per share, bringing total dividend for the year to 2.25p Operational highlights · Continued market outperformance of c.3% · Recently opened trading sites performing very strongly · Invested further in organic growth - another 18 branches opened during 2011 · Divested non-core operations, increased focus on three core markets of insulation & energy management, interiors and exteriors · £5m of annual cost savings identified from further rationalisation of branch network - total sites as at 31 December 2011: 715 (2010: 748)

http://www.investegate.co.uk/Article.aspx?id=201203140700182961Z

Sausage roll maker Greggs (GRG) reported a 1.1% rise in adjusted pre-tax profits for the year ended 31st December 2011 to 53.1 million pounds, benefiting from the roll out of coffee machines to all its stores resulting in record sales of 17.3 million cups. The baker also opened a net of 84 new shops and plans to open a further 90 in 2012. The firm enjoyed success with the trial sale of frozen sausage rolls in Iceland stores and since October the product was sold in all 750 of its supermarkets across the UK. The shares declined by 10p to 548p.